Advice
Following an abbreviated submission.
Accepted for restricted use within NHS Scotland.
Avonex is a liquid formulation which replaces a powder formulation of the same strength that requires reconstitution. It is supplied at the same price. This product is used for the treatment of selected ambulatory patients with relapsing-remitting multiple sclerosis under the provision of a risk-sharing scheme between the Scottish Executive and the manufacturer.
Download detailed advice19KB (PDF)
Medicine details
- Medicine name:
- Avonex® liquid (Interferon beta 1a)
- SMC ID:
- 58/03
- Indication:
- Ambulatory patients with relapsing multiple sclerosis (MS)
- Pharmaceutical company
- Biogen Idec Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 10 November 2003